🇺🇸 FDA

Intelligence · Clinical Pipeline

Disc Medicine Pipeline

All ClinicalTrials.gov programs at Disc Medicine — phase, modality, and trial IDs.

Programs
308

Quick answer

Disc Medicine has 308 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. EXENATIDE , VERAPAMIL

    Disc Medicine

    type 1 diabetes mellitus

    phase 2 small molecule active

    1 trial

  2. Erbitux 5 mg/mL solution for infusion

    Disc Medicine

    Unknown primary tumour of the head and neck

    phase 2 small molecule active

    1 trial

  3. Esmolol HCl LYO Orpha 2500 mg poeder voor concentraat voor oplossing voor infusie, Milrinon Hikma 1 mg/ml oplossing voor injectie, Dobutamine-hameln 5 mg/ml i.v. infusievloeistof, oplossing voor infusie

    Disc Medicine

    Cardiogenic shock

    phase 2 small molecule active

    1 trial

  4. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  5. Folinezuur Kalceks 10 mg/ml oplossing voor injectie/infusie, Paclitaxel Fresenius Kabi 6 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie, Docetaxel Eugia 20 mg/ml, concentraat voor oplossing voor intraveneuze infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 small molecule active

    1 trial

  6. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

  7. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Disc Medicine

    Sjögren's syndrome

    phase 2 small molecule active

    1 trial

  8. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Disc Medicine

    Primary membranous nephropathy

    phase 2 small molecule active

    1 trial

  9. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  10. Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  11. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  12. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  13. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  14. IMCIVREE 10 mg/ml solution for injection

    Disc Medicine

    ROHHAD syndrome

    phase 2 small molecule active

    1 trial

  15. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  16. IPILIMUMAB, MELPHALAN , NIVOLUMAB

    Disc Medicine

    metastasized melonama uveal

    phase 2 small molecule active

    1 trial

  17. Idefirix 11 mg powder for concentrate for solution for infusion

    Disc Medicine

    neuromyelitis optica spectrum disorder, devic disease

    phase 2 small molecule active

    1 trial

  18. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  19. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric peritoneal metastases

    phase 2 small molecule active

    1 trial

  20. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  23. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  24. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  25. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  26. LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  27. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  28. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  29. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  30. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  31. Mekinist 0.5 mg film-coated tablets

    Disc Medicine

    Neurofibromatosis type 1

    phase 2 small molecule active

    1 trial

  32. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  33. Mesenchymal stem cells, Suspension and solvent for suspension for injection

    Disc Medicine

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  34. Mineral-enriched powder

    Disc Medicine

    Iron Deficiency

    phase 2 other completed

    1 trial

  35. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  36. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  37. NaCl 0,9%, Deferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση

    Disc Medicine

    Subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  38. Natriumthiosulfat 25%

    Disc Medicine

    Raynaud’s phenomenon

    phase 2 small molecule active

    1 trial

  39. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  40. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  41. PEGINTERFERON ALFA-2A , TIL cells, Zirconium Zr 89 crefmirlimab berdoxam

    Disc Medicine

    Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  42. PYRIMETHAMINE, LENALIDOMIDE, PANOBINOSTAT

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  43. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  44. Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie

    Disc Medicine

    MDS with excess blasts, MDS/AML or AML patients

    phase 2 small molecule active

    1 trial

  45. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  46. RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

    Disc Medicine

    Myelofibrosis

    phase 2 other active

    1 trial

  47. Rybelsus 7 mg tablets, Kerendia 20 mg film-coated tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  48. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

Frequently asked questions

How many pipeline programs does Disc Medicine have?

308 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.